Company Overview and News
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
497 Table of Contents Index to Financial Statements Filed Pursuant to Rule 497 Registration No. 333-214767 PROSPECTUS SUPPLEMENT (To prospectu
POS EX As filed with the Securities and Exchange Commission on May 9, 2018 Securities Act File No. 333-214767
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) reported first-quarter 2018 loss of 8 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents but narrower than the year-ago loss of 12 cents. However, excluding gains related to a change in fair value of warrant liability, the company reported a loss of 6 cents per share.
Like income? If you’re reading this, then you likely do. And odds are good you’re more than a little familiar with the usual suspects … utilities stocks like Southern Co (NYSE:SO), or diversified healthcare giant Pfizer Inc. (NYSE:PFE). The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the market has to offer.
Hercules Capital continues to display an appealing risk-reward combination after the company released solid Q1-2018 results.
Good day, ladies and gentlemen, and welcome to the Insmed First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded.
Ares Capital Corp. has strong underwriting practices reflected in low non-accruals, and a debt investment portfolio that accentuates capital preservation.
The following slide deck was published by Hercules Capital, Inc. in conjunction with their 2018 Q1 earnings call.
LendingClub Corporation (LC - Free Report) is slated to announce first-quarter 2018 results on May 8, after the market closes. Its earnings and revenues are projected to grow year over year. In the last reported quarter, the company’s adjusted earnings lagged the Zacks Consensus Estimate. While the fourth quarter witnessed higher revenues, an increase in expenses was the undermining factor. Also, LendingClub does not have an impressive earnings surprise history.
Hercules Capital, Inc.’s (HTGC - Free Report) first-quarter 2018 net investment income of 31 cents per share beat the Zacks Consensus Estimate by a penny. Also, the figure was 10.7% above the year-ago quarter level. Results reflected higher revenues, growth in investment portfolio and decrease in operating expenses. However, a fall in net asset value was an undermining factor. Distributional Net Operating Income came in at $28.
Good day, ladies and gentlemen, and welcome to the Hercules Capital Q1 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instruction will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Comparison with all other baby bonds that pay a fixed rate and have less than 10 years to maturity.
7h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
8h - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
as of ET